These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

309 related items for PubMed ID: 29679515

  • 1. The influence of mTOR inhibitors on the incidence of CMV infection in high-risk donor positive-recipient negative (D+/R-) kidney transplant recipients.
    Cristelli MP, Esmeraldo RM, Pinto CM, Sandes-Freitas TV, Felipe C, Lobo CF, Viana L, Mansur J, Stopa S, Santos DWC, Grenzi PC, Aguiar WF, Tedesco-Silva H, Pestana JOM.
    Transpl Infect Dis; 2018 Aug; 20(4):e12907. PubMed ID: 29679515
    [Abstract] [Full Text] [Related]

  • 2. The effect of anti-thymocyte globulin and everolimus on the kinetics of cytomegalovirus viral load in seropositive kidney transplant recipients without prophylaxis.
    Basso G, Felipe CR, Cristelli MP, Mansur Siliano J, Viana L, Ferreira Brigido AN, Stopa Martins SB, de Castro Lima Santos DW, Aguiar WF, Tedesco-Silva Junior H, Medina-Pestana JO.
    Transpl Infect Dis; 2018 Aug; 20(4):e12919. PubMed ID: 29797676
    [Abstract] [Full Text] [Related]

  • 3. Use of mTOR inhibitor as prophylaxis for cytomegalovirus disease after kidney transplantation: A natural experiment.
    Cristelli MP, Felipe CR, Prizmic PSS, de Azevedo VFD, Viana LA, Tavares MG, Wagner de Castro Lima Santos D, de Paula MI, Medina-Pestana JO, Tedesco-Silva Junior H.
    Clin Transplant; 2019 Oct; 33(10):e13689. PubMed ID: 31400155
    [Abstract] [Full Text] [Related]

  • 4. Incidence and risk factors associated with cytomegalovirus infection after the treatment of acute rejection during the first year in kidney transplant recipients receiving preemptive therapy.
    Felipe C, Ferreira AN, de Paula M, Viana L, Cristelli M, Medina Pestana J, Tedesco-Silva H.
    Transpl Infect Dis; 2019 Dec; 21(6):e13106. PubMed ID: 31081566
    [Abstract] [Full Text] [Related]

  • 5. The impact of everolimus in reducing cytomegalovirus events in kidney transplant recipients on steroid-avoidance strategy: 3-year follow-up of a randomized clinical trial.
    de Sandes-Freitas TV, Pinheiro PMA, Sales MLMBO, Girão CM, Campos ÉF, Esmeraldo RM.
    Transpl Int; 2018 Dec; 31(12):1345-1356. PubMed ID: 29969826
    [Abstract] [Full Text] [Related]

  • 6. Fewer cytomegalovirus complications after kidney transplantation by de novo use of mTOR inhibitors in comparison to mycophenolic acid.
    Radtke J, Dietze N, Spetzler VN, Fischer L, Achilles EG, Li J, Scheidat S, Thaiss F, Nashan B, Koch M.
    Transpl Infect Dis; 2016 Feb; 18(1):79-88. PubMed ID: 26707694
    [Abstract] [Full Text] [Related]

  • 7. Preemptive anti-cytomegalovirus therapy in high-risk (donor-positive, recipient-negative cytomegalovirus serostatus) kidney transplant recipients.
    Hasegawa J, Hatakeyama S, Wakai S, Omoto K, Okumi M, Tanabe K, Mieno M, Shirakawa H.
    Int J Infect Dis; 2017 Dec; 65():50-56. PubMed ID: 28986314
    [Abstract] [Full Text] [Related]

  • 8. Donor-Specific Anti-Human Leukocyte Antigens Antibodies, Acute Rejection, Renal Function, and Histology in Kidney Transplant Recipients Receiving Tacrolimus and Everolimus.
    Ferreira A, Felipe C, Cristelli M, Viana L, Basso G, Stopa S, Mansur J, Ivani M, Bessa A, Ruppel P, Aguiar W, Campos E, Gerbase-DeLima M, Proença H, Tedesco-Silva H, Medina-Pestana J.
    Am J Nephrol; 2017 Dec; 45(6):497-508. PubMed ID: 28511172
    [Abstract] [Full Text] [Related]

  • 9. Cytomegalovirus risk factors in renal transplantation with modern immunosuppression.
    Bataille S, Moal V, Gaudart J, Indreies M, Purgus R, Dussol B, Zandotti C, Berland Y, Vacher-Coponat H.
    Transpl Infect Dis; 2010 Dec; 12(6):480-8. PubMed ID: 20629971
    [Abstract] [Full Text] [Related]

  • 10. Conversion from tacrolimus-mycophenolate mofetil to tacrolimus-mTOR immunosuppression after kidney-pancreas transplantation reduces the incidence of both BK and CMV viremia.
    Knight RJ, Graviss EA, Nguyen DT, Kuten SA, Patel SJ, Gaber L, Gaber AO.
    Clin Transplant; 2018 Jun; 32(6):e13265. PubMed ID: 29676018
    [Abstract] [Full Text] [Related]

  • 11. Reduced Incidence of Cytomegalovirus Infection in Kidney Transplant Recipients Receiving Everolimus and Reduced Tacrolimus Doses.
    Tedesco-Silva H, Felipe C, Ferreira A, Cristelli M, Oliveira N, Sandes-Freitas T, Aguiar W, Campos E, Gerbase-DeLima M, Franco M, Medina-Pestana J.
    Am J Transplant; 2015 Oct; 15(10):2655-64. PubMed ID: 25988935
    [Abstract] [Full Text] [Related]

  • 12. Cytomegalovirus disease in de novo kidney-transplant recipients: comparison of everolimus-based immunosuppression without prophylaxis with mycophenolic acid-based immunosuppression with prophylaxis.
    Manière L, Noble J, Terrec F, Bennani HN, Chevallier E, Janbon B, Germi R, Bugnazet M, Imerzoukene F, Malvezzi P, Rostaing L, Jouve T.
    Int Urol Nephrol; 2021 Mar; 53(3):591-600. PubMed ID: 33058036
    [Abstract] [Full Text] [Related]

  • 13. CMV and BKPyV Infections in Renal Transplant Recipients Receiving an mTOR Inhibitor-Based Regimen Versus a CNI-Based Regimen: A Systematic Review and Meta-Analysis of Randomized, Controlled Trials.
    Mallat SG, Tanios BY, Itani HS, Lotfi T, McMullan C, Gabardi S, Akl EA, Azzi JR.
    Clin J Am Soc Nephrol; 2017 Aug 07; 12(8):1321-1336. PubMed ID: 28576905
    [Abstract] [Full Text] [Related]

  • 14. Cytomegalovirus infection in heart transplantation: A single center experience.
    Echenique IA, Angarone MP, Rich JD, Anderson AS, Stosor V.
    Transpl Infect Dis; 2018 Aug 07; 20(4):e12896. PubMed ID: 29602266
    [Abstract] [Full Text] [Related]

  • 15. Increased risk of breakthrough infection among cytomegalovirus donor-positive/recipient-negative kidney transplant recipients receiving lower-dose valganciclovir prophylaxis.
    Stevens DR, Sawinski D, Blumberg E, Galanakis N, Bloom RD, Trofe-Clark J.
    Transpl Infect Dis; 2015 Apr 07; 17(2):163-73. PubMed ID: 25661673
    [Abstract] [Full Text] [Related]

  • 16. Patterns of cytomegalovirus infection in simultaneous kidney-pancreas transplant recipients receiving tacrolimus, mycophenolate mofetil, and prednisone with ganciclovir prophylaxis.
    Lo A, Stratta RJ, Egidi MF, Shokouh-Amiri MH, Grewal HP, Kisilisik AT, Trofe J, Alloway RR, Gaber LW, Gaber AO.
    Transpl Infect Dis; 2001 Mar 07; 3(1):8-15. PubMed ID: 11429034
    [Abstract] [Full Text] [Related]

  • 17. Cytomegalovirus prophylaxis in seropositive renal transplant recipients receiving thymoglobulin induction therapy: Outcome and risk factors for late CMV disease.
    Reusing JO, Feitosa EB, Agena F, Pierrotti LC, Azevedo LSF, Kotton CN, David-Neto E.
    Transpl Infect Dis; 2018 Oct 07; 20(5):e12929. PubMed ID: 29809309
    [Abstract] [Full Text] [Related]

  • 18. Prospective randomized study comparing everolimus and mycophenolate sodium in de novo kidney transplant recipients from expanded criteria deceased donor.
    Ferreira AN, Felipe CR, Cristelli M, Viana L, Mansur J, de Paula M, Wagner D, de Marco R, Gerbase-DeLima M, Proença H, Aguiar W, Medina-Pestana J, Tedesco-Silva Junior H.
    Transpl Int; 2019 Nov 07; 32(11):1127-1143. PubMed ID: 31278785
    [Abstract] [Full Text] [Related]

  • 19. Choice of induction regimens on the risk of cytomegalovirus infection in donor-positive and recipient-negative kidney transplant recipients.
    Luan FL, Samaniego M, Kommareddi M, Park JM, Ojo AO.
    Transpl Infect Dis; 2010 Dec 07; 12(6):473-9. PubMed ID: 20576019
    [Abstract] [Full Text] [Related]

  • 20. Safety profile comparing azathioprine and mycophenolate in kidney transplant recipients receiving tacrolimus and corticosteroids.
    Cristelli MP, Tedesco-Silva H, Medina-Pestana JO, Franco MF.
    Transpl Infect Dis; 2013 Aug 07; 15(4):369-78. PubMed ID: 23701592
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.